A 57-year-old with limited retirement savings seeks advice on investing a $70,000 surplus. Currently contributing maximally to 401(k) and Roth IRA accounts, they aim to work until 70 and require $3,500 monthly in retirement. Vanguard robo-advisors are considered for managing the funds.

xLean Robotics unveiled the xLean TR1, a dual-form AI cleaning robot at IFA 2025. The innovative robot transforms between handheld and robotic modes, offering both spot and deep cleaning capabilities with self-evolving intelligence. A global Kickstarter launch is planned.

Rosen Law Firm is investigating potential securities claims against Vera Bradley, Inc. (NASDAQ: VRA) following disappointing first-quarter results and a subsequent stock drop. Investors who purchased Vera Bradley securities may be eligible for compensation. Contact Rosen Law Firm for more information.

Hemogenyx Pharmaceuticals plc (LSE:HEMO) announced it raised £620,000 via convertible loan notes to support its HG-CT-1 clinical trial for acute myeloid leukemia. The funds will extend the company's financial resources and allow continued progress. Conversion is expected after mid-November.

Mindbreeze's latest GenAI Confidence Index reveals a significant increase in enterprise confidence regarding GenAI implementation, particularly among top executives. The survey highlights rising belief in vendor capabilities and shifting reasons for delayed adoption. Customer service leads anticipated applications.

The Bob & Dolores Hope Foundation commemorated the 80th anniversary of WWII's end with a ceremony aboard the USS Missouri in Pearl Harbor. Eight surviving crewmembers and other WWII veterans attended the event marking the Japanese surrender. The ceremony occurred precisely 80 years after the war's conclusion.

Record-high gold prices are prompting many Australians to sell unused gold. Gold Exchange Universe, led by Talal Barakat, is experiencing increased business due to its transparent and trustworthy service, offering top market payouts and same-day cash payments.

BoldAge PACE, led by CEO Mary Austin, marked National PACE Month by highlighting its integrated care model for seniors. The program emphasizes holistic care, combining medical services, social support, and daily living assistance to help older adults remain independent at home.

Nvidia's "physical AI" vision has boosted humanoid robot development, but high manufacturing costs, according to a new DIGITIMES report, will limit market penetration to just 0.2% this year. Mass adoption hinges on cost reductions, not solely AI advancements.

Ferrari (RACE) announced the completion of its eighth share buyback tranche, purchasing over 67,000 shares for approximately €22.4 million on Euronext Milan and over $5.8 million on the NYSE. This is part of a larger €2 billion buyback program.

LPL Financial's chief technical strategist, Adam Turnquist, anticipates increased market volatility in September. He notes historical seasonal weakness, but also highlights the potential for strong performance depending on prevailing market conditions and key economic indicators. Turnquist emphasizes the importance of upcoming economic data.

Hacksaw Gaming's popular slots are now available on BetMGM Casino in Pennsylvania, marking another milestone in their growing partnership. This expansion follows their successful collaboration in Ontario and other jurisdictions. BetMGM continues to prioritize responsible gaming.

500 Global and dcamp announced a strategic partnership to help Korean startups expand into the US market. The collaboration will leverage both organizations' expertise to support Korean entrepreneurs seeking global growth. Selected startups will participate in 500 Global's accelerator program in Silicon Valley.

Pope Leo XIV met with Rev. James Martin, a prominent LGBTQ+ advocate, signaling continued support for LGBTQ+ inclusion within the Catholic Church. The meeting, days before a major LGBTQ+ pilgrimage to the Vatican, reinforces the church's commitment to welcoming all.

Oslo University Hospital will conduct a phase 2 trial of Tikomed's ILB® for ALS, comparing it to Riluzole. The 116-patient study, starting in early 2026, will involve a double-blind phase followed by an open-label extension. Results are expected in 2028.